Study for Rasagiline Effect on Sleep Trial(REST)in Parkinson's Disease (PD)

Teva Pharmaceuticals logo

Teva Pharmaceuticals

Status

Completed

Conditions

Parkinson's Disease

Treatments

Drug: Rasagiline mesylate

Study type

Observational

Funder types

Industry

Identifiers

NCT01032486
TNC-RAS-PD/01
REST (Other Identifier)

Details and patient eligibility

About

The main objective of this study is to evaluate the effect of Azilect® on sleep disturbances in Parkinson's Disease patients, after 2 months of treatment.

Enrollment

120 patients

Sex

All

Volunteers

No Healthy Volunteers

Inclusion criteria

idiopathic Parkinson's disease. eligible to Azilect® treatment as per Canadian product monograph

Exclusion criteria

exclusion (e.g. drug-drug interactions, contraindications, warnings and precautions) based on the Canadian product monograph. investigational drug within 30 days prior to study use of Azilect® or selegiline within 60 days prior to study significant medical condition

Trial design

120 participants in 1 patient group

Azilect
Description:
Subjects with a diagnosis of idiopathic Parkinson's disease eligible to Azilect® treatment based on the investigator's clinical assessment and according to the Canadian product monograph.
Treatment:
Drug: Rasagiline mesylate

Trial contacts and locations

0

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems